Trial · NCT07904884
MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
NCT07904884, Not applicable, Not yet recruiting, First Affiliated Hospital of Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC ). Trials, record NCT07904884. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904884
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
- NCT number
- NCT07904884
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 310 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Acute Myeloid Leukemia
- Interventions
- RIC, MAC
- First posted
- 2026-10-29
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year relapse-free survival (RFS) | 2 years after randomization | Relapse-free survival is defined as the time from randomization until disease relapse or death from any cause, whichever occurs first. Patients who are alive without relapse will be censored at the date of last follow-up. |
| Secondary | Overall survival (OS) | 2 years after randomization | Overall survival is defined as the time from randomization to death from any cause. Patients alive at last follow-up will be censored. |
| Secondary | Non-relapse mortality (NRM) | 2 years after randomization | Non-relapse mortality is defined as death without prior disease relapse. Cumulative incidence of non-relapse mortality will be estimated, with relapse treated as a competing risk. |
| Secondary | Cumulative incidence of relapse | 2 years after randomization | Disease relapse defined as hematologic recurrence of FLT3-ITD mutated acute myeloid leukemia. Cumulative incidence of relapse will be estimated, with death without relapse treated as a competing risk. |
| Secondary | GVHD-free and relapse-free survival (GRFS) | 2 years after randomization | GVHD-free, relapse-free survival is defined as time from randomization until grade III-IV acute GVHD, chronic GVHD requiring systemic immunosuppression, leukemia relapse, or death from any cause, whichever occurs first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904884
GET https://conductscience.org/api/trials/v1/NCT07904884/registered